Advanced Medical Solutions (LON: AMS) shares down 26% - that seems a bit much

Advanced Medical Solutions (LON: AMS) shares are down 26% this morning. AMS shares have been hit by an announcement to the market. Sales in the US are going to be lower than previously thought, profits are going to be down. As we do keep repeating there is always an art to reading such corporate announcements and the usual practice is that the important information is further down. After the soft soaping about lesser matters. 

The first part of the announcement is disappointing but certainly not worth the reaction: “We therefore believe it to be prudent to remove this royalty in its entirety from Q4 2023 guidance onwards. The total 2023 full year impact of the lower royalty is expected to be a reduction of £2 million to adjusted pre-tax profit. In FY24 and FY25, the removal of the royalty is expected to reduce adjusted pre-tax profit by £4 million per annum with a similar pro-rata impact in FY26 until the end of the agreement in September 2026.” Well, yes, no one’s happy with that. Of course some of it might get written back over time. But this agreement was only to last another two years anyway. And compared to the £25 to £30 million sort of range of annual profits without this it could be regarded as excessive to take 25% off the market capitalisation.

r

Advanced Medical Solutions share price from Google Finance

It’s the next bit, lower down the announcement, that might really causing the worries: “As part of its enhanced partner strategy in the US announced in March, the Group has had positive discussions with its partners and has made good progress with new agreements aimed at delivering stronger growth from early 2024 onwards. This process has taken longer than first anticipated and associated destocking has been greater and it is clear that the FY23 impact will be more significant than previously estimated, impacting revenues just in the current year.” Ah, yes, things are not so good and “we expect”. 
Uncertainty is never something we desire in corporate announcements. If we concentrate solely on the first part then the reaction looks overdone. Meaning that it’s opinions about that second part that really should drive any valuation decision here.